CA3216325A1 - A solid state form of tafamidis and a process for its preparation - Google Patents
A solid state form of tafamidis and a process for its preparation Download PDFInfo
- Publication number
- CA3216325A1 CA3216325A1 CA3216325A CA3216325A CA3216325A1 CA 3216325 A1 CA3216325 A1 CA 3216325A1 CA 3216325 A CA3216325 A CA 3216325A CA 3216325 A CA3216325 A CA 3216325A CA 3216325 A1 CA3216325 A1 CA 3216325A1
- Authority
- CA
- Canada
- Prior art keywords
- benzoxazole
- carboxylic acid
- dichlorophenyi
- tafamidis
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382362.8 | 2021-04-26 | ||
| EP21382362.8A EP4083027A1 (en) | 2021-04-26 | 2021-04-26 | A solid state form of tafamidis and a process for its preparation |
| PCT/EP2022/060716 WO2022229026A1 (en) | 2021-04-26 | 2022-04-22 | A solid state form of tafamidis and a process for its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3216325A1 true CA3216325A1 (en) | 2022-11-03 |
Family
ID=75746555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3216325A Pending CA3216325A1 (en) | 2021-04-26 | 2022-04-22 | A solid state form of tafamidis and a process for its preparation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240208915A1 (https=) |
| EP (2) | EP4083027A1 (https=) |
| JP (1) | JP2024515770A (https=) |
| CN (1) | CN117255781A (https=) |
| BR (1) | BR112023022116A2 (https=) |
| CA (1) | CA3216325A1 (https=) |
| MX (1) | MX2023012460A (https=) |
| WO (1) | WO2022229026A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250042864A1 (en) * | 2021-11-17 | 2025-02-06 | Teva Pharmaceuticals International Gmbh | Solid state form of tafamidis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800237C (en) | 2002-12-19 | 2016-05-17 | The Scripps Research Institute | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| RU2565066C2 (ru) * | 2010-04-21 | 2015-10-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза |
| RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| PT4349406T (pt) | 2014-09-08 | 2026-02-04 | Pfizer | Formas sólidas cristalinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol para utilização como medicamento |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| EP3969443B1 (en) | 2019-05-16 | 2024-11-20 | Teva Pharmaceuticals International GmbH | Solid state forms of tafamidis and salts thereof |
| US20220251052A1 (en) * | 2019-07-04 | 2022-08-11 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021019448A1 (en) | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| US12522573B2 (en) * | 2020-10-19 | 2026-01-13 | Alivus Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
-
2021
- 2021-04-26 EP EP21382362.8A patent/EP4083027A1/en not_active Withdrawn
-
2022
- 2022-04-22 JP JP2023565586A patent/JP2024515770A/ja active Pending
- 2022-04-22 CA CA3216325A patent/CA3216325A1/en active Pending
- 2022-04-22 US US18/288,195 patent/US20240208915A1/en active Pending
- 2022-04-22 WO PCT/EP2022/060716 patent/WO2022229026A1/en not_active Ceased
- 2022-04-22 MX MX2023012460A patent/MX2023012460A/es unknown
- 2022-04-22 CN CN202280030391.4A patent/CN117255781A/zh active Pending
- 2022-04-22 BR BR112023022116A patent/BR112023022116A2/pt unknown
- 2022-04-22 EP EP22724736.8A patent/EP4330237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240208915A1 (en) | 2024-06-27 |
| WO2022229026A1 (en) | 2022-11-03 |
| BR112023022116A2 (pt) | 2024-01-09 |
| EP4083027A1 (en) | 2022-11-02 |
| CN117255781A (zh) | 2023-12-19 |
| EP4330237A1 (en) | 2024-03-06 |
| JP2024515770A (ja) | 2024-04-10 |
| MX2023012460A (es) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9884869B2 (en) | Ibrutinib solid forms and production process therefor | |
| CN110494423B (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
| JP2017505347A (ja) | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 | |
| US20250243223A1 (en) | Solid state forms of ixazomib citrate | |
| US20240208915A1 (en) | A solid state form of tafamidis and a process for its preparation | |
| CN110903239A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
| US20230322755A1 (en) | Crystal of compound x7 hydrochloride and its preparation method and application | |
| CN114195693A (zh) | 一种酰胺化合物的晶型及其制备方法 | |
| US8946441B2 (en) | Polymorphs of an active pharmaceutical ingredient | |
| US12202834B2 (en) | Solid state forms of oclacitinib maleate | |
| WO2018138272A1 (en) | Eluxadoline crystalline form and process for the preparation thereof | |
| US20240391933A1 (en) | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide | |
| TW200825092A (en) | A method for reducing the level of AED in atorvastatin calcium sample | |
| JP5847567B2 (ja) | 活性医薬成分の結晶形態 | |
| US12528795B2 (en) | Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof | |
| CN114524845B (zh) | 瑞德西韦与水杨酸的共晶及其制备方法 | |
| US20260103462A1 (en) | Different forms of 6-chloro-2-ethyl-n-(4-(4-(4(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide | |
| US20260070928A1 (en) | Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof | |
| US20240270733A1 (en) | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof | |
| US20250340505A1 (en) | Solid-state form of hydrate of calcium oxybate, method of making and use | |
| CN121293190A (zh) | 替戈拉生化合物的晶型及其制备方法和用途 | |
| WO2024023796A1 (en) | Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof | |
| WO2017032705A1 (en) | Crystalline form of omarigliptin | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 | |
| EP2980091A1 (en) | Novel hydrates of dolutegravir sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250418 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250418 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260410 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260410 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260417 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260417 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260422 |